At a glance
- Tesamorelin is a stabilized GHRH analogue that stimulates pituitary growth-hormone release and downstream IGF-1. It is one of the few catalogue peptides with an approved drug product—but for a very specific indication.
- FDA-approved Egrifta products are indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy. They are not indicated for general weight loss. This research vial is not Egrifta and is not a prescription or clinically equivalent product.
- Compare tesamorelin with sermorelin or modified GRF to study how stabilization changes GHRH-pathway exposure.
- Measure GH pulses and downstream IGF-1 separately from visceral-fat or other longer-term endpoints.
What TESAMORELIN is—and what the name does not establish
Tesamorelin is a stabilized GHRH analogue that stimulates pituitary growth-hormone release and downstream IGF-1. It is one of the few catalogue peptides with an approved drug product—but for a very specific indication.
Tesamorelin activates the GHRH receptor upstream of endogenous growth-hormone release. A trans-3-hexenoic-acid modification improves resistance to enzymatic breakdown. In plain language, it extends a GHRH-like signal rather than supplying HGH directly.
Questions to settle before interpreting a result
A useful TESAMORELIN study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Compare tesamorelin with sermorelin or modified GRF to study how stabilization changes GHRH-pathway exposure.
- Measure GH pulses and downstream IGF-1 separately from visceral-fat or other longer-term endpoints.
- Keep HIV-lipodystrophy trial evidence separate from general obesity, anti-aging, or performance claims.
How to read the TESAMORELIN evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Human evidence · specific population
- Design
- Visceral-fat reduction was shown in HIV lipodystrophy trials
- Finding
- Randomized studies of the regulated tesamorelin product demonstrated changes in visceral adipose tissue in adults with HIV-associated lipodystrophy. The population and indication are essential context.
- Read with care
- Keep the finding attached to the linked study’s exact material, design, population, exposure, and endpoint.
Label boundary
- Design
- Approved does not mean general weight loss
- Finding
- The approved label is narrow and explicitly distinct from routine obesity management. Product pages should preserve that distinction rather than generalizing the result.
- Read with care
- Keep the finding attached to the linked study’s exact material, design, population, exposure, and endpoint.
Mechanism comparison
- Design
- Upstream GHRH is not direct HGH
- Finding
- Tesamorelin depends on pituitary responsiveness and endogenous release. Somatropin activates growth-hormone receptors after direct exposure.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
FDA-approved Egrifta products are indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy. They are not indicated for general weight loss. This research vial is not Egrifta and is not a prescription or clinically equivalent product.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- Randomized tesamorelin trial in HIV-associated abdominal fat accumulationPeer-reviewed publication · 2010
Randomized studies of the regulated tesamorelin product demonstrated changes in visceral adipose tissue in adults with HIV-associated lipodystrophy. The population and indication are essential context. The result remains tied to the exact study material, design, population, and endpoint.
- Egrifta (tesamorelin) FDA application recordU.S. Food and Drug Administration · Linked record
The approved label is narrow and explicitly distinct from routine obesity management. Product pages should preserve that distinction rather than generalizing the result. The result remains tied to the exact study material, design, population, and endpoint.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Explore TESAMORELIN
Review available strengths, pricing, stock status, and product documentation.